BACKGROUND: The use of involved-field radiotherapy after chemotherapy for advanced @entity978 is controversial. METHODS: We randomly assigned @entity1 with previously untreated stage III or IV @entity978 who were in complete remission after hybrid chemotherapy with @entity3700 , @entity1891 , @entity4174 , @entity229 , @entity632 , @entity1732 , and @entity5713 (MOPP-ABV) to receive either no further treatment or involved-field radiotherapy. Radiotherapy consisted of 24 Gy to all initially involved nodal areas and 16 to 24 Gy to all initially involved extranodal sites. @entity1 in partial remission were treated with 30 Gy to nodal areas and 18 to 24 Gy to extranodal sites. RESULTS: Of 739 @entity1 , 421 had a complete remission; 161 of these @entity1 were assigned to no further treatment, and 172 to involved-field radiotherapy. The median follow-up was 79 months. The five-year event-free survival rate was 84 percent in the group that did not receive radiotherapy and 79 percent in the group that received involved-field radiotherapy (P=0.35). The five-year overall survival rates were 91 and 85 percent, respectively (P=0.07). Among the 250 @entity1 in partial remission after chemotherapy, the five-year event-free and overall survival rates were 79 and 87 percent, respectively. CONCLUSIONS: Involved-field radiotherapy did not improve the outcome in @entity1 with advanced-stage @entity978 who had a complete remission after MOPP-ABV chemotherapy. Radiotherapy may benefit @entity1 with a partial response after chemotherapy.

Involved-field radiotherapy for advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity4174 :: ('MESH:D011344', 'Chemical') :: ['procarbazine'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin'] @entity3700 :: ('MESH:D008466', 'Chemical') :: ['mechlorethamine'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine'] @entity978 :: ('MESH:D006689', 'Disease') :: ["Hodgkin's lymphoma"]
@entity978 :: (MESH:D006689,Disease) :: ['Hodgkin's lymphoma']
